Alterity Therapeutics’ phase II study of its lead compound ATH434 in multiple system atrophy (MSA) has been featured in an ...

ATH434 improves daily function and reduces brain iron in patients with multiple system atrophy, a rare, fatal ...

"Multiple System Atrophy Competitive Landscape"Multiple System Atrophy companies are Neuramedy Co.,Ltd, ProMIS Neurosciences, Enterin Inc., Nippon Chemiphar, CORESTEM ...

Data highlights symptom stability and enhanced efficacy signals in higher dose group –– Analysis offers valuable insights to guide ongoing ...

DUBLIN, October 16, 2025--(BUSINESS WIRE)--Theravance Biopharma, Inc. (NASDAQ: TBPH) today announced the launch of "Power in the Periphery," a new disease education campaign for healthcare ...

A school community is rallying behind a former teacher who has been diagnosed with a rare and life-limiting condition ...

Parkinson’s disease (PD) remains one of the most challenging neurodegenerative disorders to diagnose and monitor.

An update from Alterity Therapeutics ( ($AU:ATH) ) is now available. Alterity Therapeutics presented promising data on ATH434 at the 36th ...

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today ...

Tiziana Life Sciences is a buy due to its platform optionality and upcoming catalysts that outweigh its dilution risk and ...

ST. LOUIS – Amid hundreds of emails, phone calls and messages, Tim Ezell opens up about his absence from FOX 2 News in the morning and his change in his condition. During an interview in his home with ...